Allogene Therapeutics, Inc.
ALLOHealthcareNASDAQBiotechnology · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. The $459.5M market capitalization puts ALLO squarely in small-cap range for its industry. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies.
Market Cap
$459.5M
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
-2.16
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.62
ROE
-42.4%
ROA
-22.1%
Cash
$332.6M
Total Debt
$79.0M
Free CF
-$63.5M
52W Change
5.6%
Annual Financials
Cash vs Debt
Where ALLO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ALLO finished 35.32% below its 150-day moving average ($2.01) and 34.67% below its 200-day moving average ($1.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALLO overbought or oversold?
At the October 20, 2026 close, ALLO's RSI(14) was 20.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $332.6M in cash and $79.0M in debt, ALLO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$63.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -42.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $156K (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Allogene Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, ALLO has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ALLO.